- Jazz Pharmaceuticals (Nasdaq: Jazz) priced $850 million in aggregate principal amount of 3.125% exchangeable senior notes due 2030 in a private offering conducted by its subsidiary Jazz Investments I.
- The issuer also granted the initial purchasers an option to purchase an additional $150 million of bonds.
- The sale The notes are expected to close on September 6, 2024.
- The Company also repurchased ~$150 million of its common stock from purchasers of the notes in privately negotiated transactions.